Home > Oncology > Rucaparib bests chemo in relapsed ovarian cancer

Rucaparib bests chemo in relapsed ovarian cancer


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
The Lancet Oncology
Reuters Health - 28/03/2022 - Results of the ARIEL4 study support the use of the PARP inhibitor rucaparib as an alternative to chemotherapy for patients with relapsed, BRCA1- or BRCA2-mutated ovarian cancer. "To our knowledge, ARIEL4 is the first study to compare a PARP inhibitor with standard-of-care platinum and non-platinum-based chemotherapy in patients with germline or somatic BRCA1 or BRCA2 mutations and relapsed ovarian carcinoma," researchers report in The Lancet Oncology. "Our patient population is also distinct from that of previous studies because it included patients with platinum-resistant, partially platinum-sensitive, and fully platinum-sensitive disease. In this broad population, rucaparib significantly improved progression-free survival versus chemotherapy," they add. The open-label study enrolled 349 patients with relapsed, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, with 233 randomly allocated to rucaparib (...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on